Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients

View ORCID ProfileNeil R. Aggarwal, Laurel E. Beaty, View ORCID ProfileTellen D. Bennett, View ORCID ProfileNichole E. Carlson, Christopher B. Davis, Bethany M. Kwan, View ORCID ProfileDavid A. Mayer, View ORCID ProfileToan C. Ong, View ORCID ProfileSeth Russell, Jeffrey Steele, View ORCID ProfileAdane F. Wogu, Matthew K. Wynia, Richard D. Zane, View ORCID ProfileAdit A. Ginde
doi: https://doi.org/10.1101/2022.04.03.22273360
Neil R. Aggarwal
aDepartment of Medicine, University of Colorado School of Medicine, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Neil R. Aggarwal
  • For correspondence: neil.aggarwal@cuanschutz.edu
Laurel E. Beaty
bDepartment of Biostatistics and Informatics, Colorado School of Public Health, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tellen D. Bennett
cSection of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, Aurora, 80045, USA
eColorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tellen D. Bennett
Nichole E. Carlson
bDepartment of Biostatistics and Informatics, Colorado School of Public Health, Aurora, 80045, USA
eColorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nichole E. Carlson
Christopher B. Davis
dDepartment of Emergency Medicine, University of Colorado School of Medicine, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bethany M. Kwan
dDepartment of Emergency Medicine, University of Colorado School of Medicine, Aurora, 80045, USA
eColorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, 80045, USA
fDepartment of Family Medicine, University of Colorado School of Medicine, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David A. Mayer
bDepartment of Biostatistics and Informatics, Colorado School of Public Health, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David A. Mayer
Toan C. Ong
cSection of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Toan C. Ong
Seth Russell
cSection of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Seth Russell
Jeffrey Steele
gResearch Informatics, Children’s Hospital Colorado, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adane F. Wogu
bDepartment of Biostatistics and Informatics, Colorado School of Public Health, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adane F. Wogu
Matthew K. Wynia
aDepartment of Medicine, University of Colorado School of Medicine, Aurora, 80045, USA
hCenter for Bioethics and Humanities, University of Colorado, Anschutz Medical Campus, Aurora, 80045, USA
iDepartment of Health Systems Management and Policy, Colorado School of Public Health, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard D. Zane
dDepartment of Emergency Medicine, University of Colorado School of Medicine, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adit A. Ginde
dDepartment of Emergency Medicine, University of Colorado School of Medicine, Aurora, 80045, USA
eColorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, 80045, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adit A. Ginde
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background It is not known whether sotrovimab, a neutralizing monoclonal antibody (mAb) treatment authorized for early symptomatic COVID-19 patients, is effective against the SARS-CoV-2 Delta variant to prevent progression to severe disease and mortality.

Methods Observational cohort study of non-hospitalized adult patients with SARS-CoV-2 infection from October 1st 2021 - December 11th 2021, using electronic health records from a statewide health system plus state-level vaccine and mortality data. We used propensity matching to select 3 patients not receiving mAbs for each patient who received outpatient sotrovimab treatment. The primary outcome was 28-day hospitalization; secondary outcomes included mortality and severity of hospitalization.

Results Of 10,036 patients with SARS-CoV-2 infection, 522 receiving sotrovimab were matched to 1,563 not receiving mAbs. Compared to mAb-untreated patients, sotrovimab treatment was associated with a 63% decrease in the odds of all-cause hospitalization (raw rate 2.1% versus 5.7%; adjusted OR 0.37, 95% CI 0.19-0.66) and an 89% decrease in the odds of all-cause 28-day mortality (raw rate 0% versus 1.0%; adjusted OR 0.11, 95% CI 0.0-0.79), and may reduce respiratory disease severity among those hospitalized.

Conclusion Real-world evidence demonstrated sotrovimab effectiveness in reducing hospitalization and all-cause 28-day mortality among COVID-19 outpatients during the Delta variant phase.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by the National Center for Advancing Translational Sciences of the National Institutes of Health [grant numbers UL1TR002525, UL1TR002535-03S3 and UL1TR002535-04S2].

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Colorado Multiple Institutional Review Board approved the study with a waiver of informed consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 05, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients
Neil R. Aggarwal, Laurel E. Beaty, Tellen D. Bennett, Nichole E. Carlson, Christopher B. Davis, Bethany M. Kwan, David A. Mayer, Toan C. Ong, Seth Russell, Jeffrey Steele, Adane F. Wogu, Matthew K. Wynia, Richard D. Zane, Adit A. Ginde
medRxiv 2022.04.03.22273360; doi: https://doi.org/10.1101/2022.04.03.22273360
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients
Neil R. Aggarwal, Laurel E. Beaty, Tellen D. Bennett, Nichole E. Carlson, Christopher B. Davis, Bethany M. Kwan, David A. Mayer, Toan C. Ong, Seth Russell, Jeffrey Steele, Adane F. Wogu, Matthew K. Wynia, Richard D. Zane, Adit A. Ginde
medRxiv 2022.04.03.22273360; doi: https://doi.org/10.1101/2022.04.03.22273360

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (420)
  • Anesthesia (97)
  • Cardiovascular Medicine (898)
  • Dentistry and Oral Medicine (169)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (405)
  • Epidemiology (8774)
  • Forensic Medicine (4)
  • Gastroenterology (404)
  • Genetic and Genomic Medicine (1858)
  • Geriatric Medicine (178)
  • Health Economics (387)
  • Health Informatics (1288)
  • Health Policy (644)
  • Health Systems and Quality Improvement (491)
  • Hematology (206)
  • HIV/AIDS (392)
  • Infectious Diseases (except HIV/AIDS) (10549)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1750)
  • Nursing (102)
  • Nutrition (265)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (461)
  • Oncology (963)
  • Ophthalmology (281)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (263)
  • Pediatrics (556)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1842)
  • Public and Global Health (3977)
  • Radiology and Imaging (652)
  • Rehabilitation Medicine and Physical Therapy (343)
  • Respiratory Medicine (534)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)